Andreessen Horowitz backs a new molecule builder from UCLA equipped with the latest in convergence tech. And he’s aiming big
Sri Kosuri has spent years at a scientific crossroads, watching the rapidly accelerating work on synthetic biology, big data and genomics. The MIT grad spent time working as a staff scientist with George Church at the Wyss Institute. And he kept at it as a professor in chemistry at UCLA.
Now, Kosuri’s taken a leave of absence after bagging a $30 million investment from Andreessen Horowitz to see if he can take these convergent technologies in polypharmacology and create a powerful new machine for drug discovery. The upstart biotech is called Octant. And Kosuri’s shooting for something groundbreaking in the toughest fields he can find.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.